Aripiprazole use in children and adolescents: a case series


BİLDİK T. , ÖZBARAN N. B. , KUCUKKOSE M., ARDIC U. A.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.20, ss.84-93, 2010 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 20 Konu: 1
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1080/10177833.2010.11790639
  • Dergi Adı: KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
  • Sayfa Sayıları: ss.84-93

Özet

In children and adolescents, atypical antipsychotics have been largely used to treat aggression, mood instability, and psychosis. There is a growing interest in the use of aripiprazole in children and adolescents with schizophrenia, pervasive developmental disorders, and bipolar disorders. A series of 7 children and adolescents (ages 11-17 years, 5 males) were treated with aripiprazole for different psychiatric disorders. All patients had been treated previously with several psychotropic drugs. Aripiprazole was initiated at a starting dose of 2.5 or 5 mg daily and optimal dosages ranged from 5 to 10 mg daily. Six of the 7 patients appeared to benefit from aripiprazole. Neither extrapyramidal side effects nor agitation was observed in any case. Aripiprazole was well tolerated and effective in our cases and appears to be a safe and efficacious alternative in the child and adolescents. However, prospective clinical trials with a randomized placebo controlled design are needed.